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Abstract
Background: Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be
in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern
respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for
future research of drugs repurposed for COVID-19.
Methods: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of
34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified
both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical
improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive
care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence.
Discussion: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed
but also a sustained effort to integrate new evidence into a living systematic review.
Trial registration: PROSPERO 2020 CRD42020175648
Keywords: COVID-19, SARS-CoV2, Severe acute respiratory syndrome, SARS, Middle East respiratory syndrome
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Background
The coronavirus disease 2019 (COVID-19) pandemic
represents one of the deadliest and economically most
consequential outbreaks in around 100 years [1, 2]. To
date, only remdesivir (Gilead Sciences) has shown to
possibly lower the time to recovery [3, 4]. In the past,
developing antiviral agents has taken 5.9 years on aver-
age [5]. In the current crisis, it appears feasible that this
timeline will be significantly reduced if there were early
signs of efficacy. Moreover, a candidate drug could be
offered emergency use authorization by the U.S. Food
and Drug Administration and similar designations by
regulatory authorities across the world, as was the case
with remdesivir.
Drug repurposing has been a successful strategy for a
variety of therapeutic areas [6]. In the case of COVID-19,
compounds of interest include those that have previously
been found to either be clinically efficacious or have
in vitro activity against the coronaviruses that cause severe
acute respiratory syndrome (SARS) and Middle Eastern
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respiratory syndrome (MERS), which share significant
structural similarities with SARS-CoV-2, the virus that
causes COVID-19 [7, 8]. However, the existing clinical
and preclinical research studying these viruses as a whole
has never been systematically reviewed. Information on
drugs potentially active against COVID-19 is expected to
change rapidly as the results of ongoing and future studies
become available. It is crucial that both researchers and
health care providers are able to access the optimum and
most up-to-date information to inform future or ongoing
studies and provide clinical care.
The objectives for the current protocol are (1) to
systematically review which existing medications have
shown to be potentially effective against SARS or MERS
and could therefore be potentially repurposed; (2) to
present the early evidence that supports testing readily
available drugs against SARS-CoV-2; (3) to provide the
best available level of evidence for the efficacy of each
individual candidate drug; and (4) to report harmful
effects associated with use of these drugs.
Methods/design
This protocol specifies the conduct and reporting of a
systematic review in compliance with the Preferred
Reporting Items for Systematic Review and Meta-
Analysis Protocols 2015 statement (PRISMA-P) [9]. The
protocol has been registered with the International Pro-
spective Register of Systematic Reviews (PROSPERO)
and assigned the identifier CRD42020175648. This is
intended as a living systematic review that will be con-
tinuously updated via semi-automated approaches, and
updates will be published intermittently based on trig-
gers that include substantial changes to the evidence
base for any included intervention.
Data sources
Bibliographical databases for literature search include
Medline (via PubMed), Embase, the International Clinical
Trials Registry Platform (ICTRP), ClinicalTrials.gov (for
nonrandomised studies and trials with summary results),
as well as the following preprint servers: MedRxiv, BioR-
xiv, chemRxiv, Preprints.org, and the Chinese-language
server ChinaXiv. Our search strategy combines terms for
COVID-19, SARS, MERS, and their causative agents with
drug names, based on the following eligibility criteria
(see Additional file 2: Appendix).
Eligibility criteria
All clinical, in vitro, and animal studies that test
interventions used to treat diseases associated with
SARS-CoV-2, SARS-CoV, or MERS-CoV are eligible
for inclusion in the systematic review.
Study design
Single-arm and controlled studies with or without
randomisation as well as open-label or blinded designs
will be included. Future clinical studies should be
focused on agents that were found to be promising in
in vitro or in animal studies, and these should be
included here as we are aiming to identify potentially
effective treatments.
Interventions
The interventions we studied were derived from a
scoping review by the World Health Organisation
(WHO) [10]. They encompass both single-agent and
combination regimens with one or more of the following
agents: atazanavir, azithromycin, baloxavir marboxil, bari-
citinib, bevacizumab, chloroquine, colchicine, darunavir/
cobicistat, emtricitabine/tenofovir, enisamium iodide, favi-
piravir (T-705), fingolimod, ganciclovir, hydroxychloro-
quine, indinavir, lopinavir/ritonavir, mycophenolic acid/
mofetil, nelfinavir, niclosamide, nitazoxanide, nitric oxide,
novaferon, oseltamivir, pirfenidone, quercetin, remdesivir
(GS-5734), ribavirin, ruxolitinib, sirolimus, sofosbuvir,
tocilizumab, thymosin alpha-1, triazavirin, and umifenovir.
We have additionally included glucocorticosteroids (with
or without mineralocorticoids), interferons, statins, and
convalescent serum or plasma.
Comparators, participants, follow-up periods, and
languages
For clinical studies, eligible studies include patients with
mild-to-moderate or severe disease in both outpatient
and inpatient settings, with the latter including intensive
care unit (ICU) and non-ICU patients. For clinical stud-
ies to be included, participants must not just have symp-
toms compatible with COVID-19 but either laboratory
confirmation of infection of respective viruses—severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), severe acute respiratory syndrome coronavirus
(SARS-CoV), or Middle Eastern Respiratory Syndrome
Coronavirus (MERS-CoV)—or be presumed to be in-
fected on clinical grounds after careful deliberation. No
restrictions on minimum follow-up periods or language
of the articles are included. Our team includes native
speakers of various languages, and additional translator
services will be used as needed.
Animal and in vitro studies are eligible for inclusion if
they seek to provide evidence on the potential human
use of the interventions for the conditions described
above. These studies will be summarised separately from
the clinical studies in a summary of findings table and
visualised together with clinical studies illustrate the
current pipeline of evidence for early investigations into
new treatments.
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Outcomes
Studies are eligible if they include clinical endpoints
related to time to clinical improvement, time to viral
clearance, mortality, hospital admission or transfer to a
higher level of care, including transfer to an ICU or
ICU-like setting and total and ICU length of stay, pro-
portion of intubations, length of mechanical ventilation,
normalization of selected laboratory data (such as C-
reactive protein, d-dimer, lactate dehydrogenase, ferritin,
and lymphocyte count), and adverse events.
Study selection, data management, and data extraction
Two reviewers will use the same eligibility criteria to
evaluate the studies. Conflicts will be resolved by discus-
sion. Data management for the study selection process
will occur in Covidence (Veritas Health Innovation,
Melbourne, Australia). Study data will be extracted by
one reviewer and verified by a second reviewer. In
addition to the outcome measures, the following charac-
teristics of the verified RCTs will be extracted: (1) refer-
ence details (including the first author’s last name and
the publication year); (2) country of origin; (3) the
specific coronavirus studied (SARS-CoV-2, SARS-CoV,
or MERS-CoV); (4) type of cell or animal studied
(applicable only to in vitro or animal study); (5) blinded
versus open-label design (applicable to controlled
studies); (6) inclusion and exclusion criteria; (7) baseline
patient characteristics, in particular duration since onset
of symptoms, outpatient versus non-ICU versus ICU
setting, and mild-to-moderate versus severe disease; (8)
intervention(s) studied; (9) control(s, if any); (10) total
number of participants; (11) primary outcome; (12)
secondary outcome(s); (13) results; and (14) conclusions.
Corresponding authors will be contacted for clarification
where necessary.
Quality and risk of bias assessment
The quality of the available evidence will be evaluated
using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) framework [11]
and applied separately for each intervention with one or
more included studies in humans. Risk of bias will be
assessed for any randomised trials using the revised
Cochrane risk of bias tool [12], and the Risk of Bias in
Nonrandomised Studies of Interventions (ROBINS-I)
tool [11]. Animal and in vitro studies will not be
assessed for risk of bias, and a narrative review of these
studies will be done separately.
Data synthesis and analysis
The extracted data will be collated and qualitatively
synthesized via an interactive mechanism to select, sort,
and filter columns for the results tables on our website
(www.CovidDrugs.org). We will devise various pre-populated
tables that can be viewed and downloaded as well.
Tables that include a summary of findings will be de-
veloped for each treatment (incorporating multiple
outcomes per table) and included on the website as
well as in the Additional file 2: Appendix of the manu-
script and its updates.
While the review is initially focused on mapping the
status and quality of evidence for each of the treatments
that are being tested for use in treating COVID-19, we
will undertake safety and efficacy meta-analyses where
possible. Where multiple controlled studies are available
for a similar patient population, we will calculate a
relative risk with a 95% confidence interval via a
random-effects meta-analysis in RevMan, STATA, or
the R metafor package. Heterogeneity will be assessed as
τ2. Funnel plots and Egger’s test will be reported to
assess publication bias.
Living systematic review
COVID-19 is now endemic and there is a need to
identify, review, critically appraise, and synthesize new
studies in an ongoing way [13]. Following the first
complete publication of the systematic review, it will be
transformed into a living and open systematic review
[14–17]. This includes automated search updates, semi-
automated combining and de-duplicating all search re-
sults, and semi-automated updating of included study
lists and summary tables made available on the website
and in an extensible markup language (XML) stream. As
new articles or registrations are identified by daily data-
base searches, these are assigned to reviewers for screen-
ing using an alert system. Once screened, their relevance
and inclusion status will be updated on the website and
in the XML stream. The search terms will be reviewed
intermittently and updated by consensus among the re-
viewer group during meetings, and at least quarterly.
The proposed living systematic review seeks to moni-
tor the quality of evidence for repurposed drugs used in
COVID-19. Our initial focus is on providing a platform
for capturing relevant controlled studies as they are reg-
istered, completed, and reported, as well as animal and
in vitro studies that may support the need for clinical
studies. Synthesis is focused on visualising important in-
formation including the design, grading, risk of bias and
extracted summary results. As results for more trials be-
come available, the systematic review will be extended to
include individual safety and efficacy meta-analyses for
some of the interventions and outcomes. Where future
updates include meta-analyses for individual treatments
and outcomes, appropriate tests for heterogeneity and
meta-biases will be applied.
In terms of dissemination, the completed review
manuscript and intermittent updates (e.g., when the
number of included studies changes, when a conclusion
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for any intervention changes, or for any other pre-
defined triggers) will be posted to medRxiv. This ensures
that each substantial update can be cited but the
complete history and most recently available evidence is
available in one location with a single digital object
identifier (DOI).
We will adapt and use methods from natural language
processing and crowd sourcing to support the review
process, learning from recently developed tools and pro-
cesses to add non-human and crowd-based screening
and extraction [18–20]. We will open source our
methods and results and intend to crowd source future
review efforts, which may alter the number of authors
on review updates.
Discussion
This systematic review will summarize the emerging
evidence on repurposed drugs for the treatment of
COVID-19, extrapolating from early evidence for
COVID-19 itself as well as SARS and MERS. The proto-
col extends beyond synthesizing evidence about poten-
tial treatment compounds that were identified in a
scoping review by the WHO to incorporate pre-print
servers and trial registries and to become an ongoing
monitoring of the available evidence for each of the
treatments. Initial syntheses are focused on mapping the
evidence in terms of how much is available across ani-
mal, in vitro, and clinical studies, as well as the quality
and risks of bias in any clinical studies. This protocol
was written in accordance with the PRISMA-P statement
(Additional file 1) and is registered with PROSPERO.
The challenge posed by COVID-19 requires not just a
rapid review of drugs that can be repurposed but also a
sustained effort to monitor the evidence base as it
evolves. By incorporating animal and in vitro studies, the
approach should be particularly useful in prioritizing
candidates for testing in clinical studies and compare
across the broad range of drugs that have been pro-
posed. Finally, future investigators could benefit from
preliminary estimates of efficacy for power and sample
size calculations where appropriate, and their study de-
signs could inform relevant clinical safety and efficacy
endpoints as well as gaps in outcome measures that
should be incorporated into future studies.
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